4 July 2022
The Galician government supports the biotechnology company Oncostellae to advance clinical trials with new pharmaceutical compounds

julio 4, 2022

---

Santiago de Compostela, 4 July 2022. XesGalicia, an investment body dependent on the Xunta de Galicia, will participate through its Galicia…

Read More

25-28 Oct 2021
Oncostellae intensifies partnering process at BIO-Europe to outlicense OST-122, a safe and non-systemic JAK3/TYK2/ARK5 inhibitor for IBD

septiembre 30, 2021

---

Oncostellae participates at the BIO-Europe partnering event taking place on October 25-28, 2021 in a digital format. The company is in…

Read More

9 Jun 2021
Cinco firmas gallegas socias de Bioga acuden a BIO Digital 2021, la principal feria biotech del mundo

junio 11, 2021

---

Oncostellae, Celtarys Research, SunRock Biopharma, Arjuna Therapeutics y Key Biological estarán en la cita ‘on line’ que abordará cómo el sector bio…

Read More

25 Mar 2021
Jornada de Presentación de Resultados del Proyecto IO4COLON

marzo 24, 2021

---

ONCOSTELLAE se complace en invitaros a la jornada de cierre del proyecto IO4COLON, “Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos…

Read More

23-25 Mar 2020
Oncostellae participates at the BIO-Europe partnering conference in Paris

febrero 22, 2020

---

Oncostellae will assist at the 14th Annual International Partnering Conference during the BIO-Europe Spring event that takes place from March 23-25,…

Read More

February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis

febrero 21, 2020

---

Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….

Read More

11 October 2019
IO4COLON project progress

febrero 21, 2020

---

Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos en tratamiento de cáncer de colon. El pasado viernes (11 de octubre…

Read More

May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing

febrero 20, 2020

---

Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…

Read More

10 Dec 2018
GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study

marzo 24, 2019

---

OST-122, a novel, gut-restricted Jak3/Tyk2 inhibitor for the local treatment of gastrointestinal diseases, has completed the first part of a randomized,…

Read More

23 Jul 2018
Oncostellae initiated clinical development of OST-122

marzo 24, 2019

---

Oncostellae has started today a first-in-human study of OST-122, its novel, gut-restricted Jak3/Tyk2 inhibitor that is being developed for the local…

Read More